Clinical Comparison: Switching Between Treatment Options
Understanding Your Options: Change From Wegovy to Mounjaro Mechanisms
When considering a change from Wegovy to Mounjaro, the fundamental difference lies in their receptor targets and mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone to reduce appetite and promote satiety through brain appetite centres. Mounjaro contains tirzepatide, which uniquely targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously, creating a dual agonist approach to weight management. This mechanistic difference may explain why some patients considering a change from Wegovy to Mounjaro report different tolerance profiles and effectiveness patterns. Both prescription-only medicines require clinical assessment and work alongside a reduced-calorie diet and increased physical activity for optimal results.
The decision to change from Wegovy to Mounjaro often stems from individual response variations, side effect profiles, or dosing preferences. EverydayMeds provides both treatments through our GPhC-registered pharmacy (#9012878), allowing your prescriber to evaluate which mechanism aligns best with your clinical needs. Wegovy's established GLP-1 pathway offers proven efficacy through the STEP trial programme, while Mounjaro's dual receptor activation represents a newer approach with distinct clinical characteristics. Understanding these differences helps inform discussions with healthcare providers about potential treatment switches or initial medication selection.
Pricing Comparison: Wegovy vs Mounjaro Treatment Costs
When evaluating a change from Wegovy to Mounjaro, cost considerations play a significant role in treatment decisions. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. Our Getting Started bundles provide convenient dose progression options, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99. New customers benefit from code FIRST40 applied at checkout, while returning customers use DOSE25, with these discounts already reflected in our listed prices.
Mounjaro pricing follows a different structure reflecting its unique dosing schedule and dual mechanism formulation. Both treatments represent significant investments in long-term weight management, and the choice to change from Wegovy to Mounjaro should consider not just individual pen costs but the complete treatment journey including dose escalation phases. EverydayMeds' bundle options for both medications provide convenience benefits including Reliable Supply continuity and reduced ordering frequency, supporting consistent treatment adherence regardless of which option you and your prescriber select.
Clinical Evidence: Research Supporting Treatment Switching Decisions
The STEP clinical trial programme demonstrates Wegovy's efficacy profile, with STEP 1 showing approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions, as reported by Wilding et al. in the New England Journal of Medicine, 2021. These results provide a clinical benchmark for patients considering their current treatment effectiveness or contemplating a change from Wegovy to Mounjaro based on individual response patterns. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, adding another dimension to treatment selection criteria.
Mounjaro's clinical evidence stems from different trial designs and populations, making direct comparison inappropriate but providing distinct efficacy data for consideration. Patients may consider a change from Wegovy to Mounjaro based on individual treatment response, side effect tolerance, or clinical factors identified during ongoing medical supervision. Both medications require prescription-only access and regular clinical monitoring to ensure appropriate treatment outcomes and safety profile management throughout the treatment period.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy's semaglutide formulation works as a GLP-1 receptor agonist, closely mimicking the body's natural incretin hormone system that regulates appetite and food intake. Once injected weekly via the FlexTouch pen system, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings between meals. This mechanism slows gastric emptying, meaning food remains in the stomach longer, contributing to sustained satiety after smaller meal portions. The medication may help reduce the psychological drive to eat by influencing reward pathways associated with food intake. Additionally, GLP-1 receptor activation supports healthy blood glucose regulation, though Wegovy is specifically licensed for weight management rather than diabetes treatment, unlike Ozempic which contains the same active ingredient but is licensed for type 2 diabetes only.
Ordering Process: Accessing Both Treatment Options
EverydayMeds streamlines access to both Wegovy and Mounjaro through our comprehensive online clinical assessment taking approximately 3 minutes to complete, covering medical history, current medications, and weight management goals. Following submission, our qualified prescribers review your assessment within standard 3 working days or express 24-hour service, evaluating suitability for either treatment option based on MHRA licensing criteria and clinical guidelines. Once approved, both medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity throughout transit. Our process supports patients whether starting their first GLP-1 treatment or considering a change from Wegovy to Mounjaro under appropriate medical supervision. All consultations include ongoing support and monitoring recommendations to optimise treatment outcomes safely.
Storage Requirements: Practical Differences Between Treatments
Storage considerations may influence your decision to change from Wegovy to Mounjaro, particularly for frequent travellers or those with varying refrigeration access. Wegovy requires refrigeration at 2–8°C before first use but offers significant flexibility with up to 6 weeks storage at room temperature below 30°C once removed from the fridge, providing superior travel convenience compared to many other injectable medications. Mounjaro has more restrictive room temperature storage limits at 21 days maximum, making Wegovy advantageous for extended travel periods or irregular storage situations. Both medications use pre-filled pen devices for straightforward weekly administration, though the FlexTouch system design differs between formulations. Proper storage maintains medication potency and safety throughout the prescribed dose escalation schedule, whether continuing current treatment or managing a change from Wegovy to Mounjaro under clinical guidance.
Treatment Switching: Medical Considerations for Changing Medications
The decision to change from Wegovy to Mounjaro requires careful medical evaluation considering current treatment response, side effect experiences, and individual clinical factors that might favour one mechanism over another. Some patients report different gastrointestinal tolerance between semaglutide and tirzepatide formulations, while others may benefit from Mounjaro's dual receptor targeting approach based on their metabolic profile. Timing of treatment switches typically involves completing current dose cycles and allowing appropriate washout periods as determined by prescriber recommendations. Your medical history, concurrent medications, and previous treatment responses all inform the clinical decision-making process when considering medication changes.
EverydayMeds supports treatment transitions through comprehensive clinical oversight, ensuring continuity of care whether maintaining current therapy or implementing a change from Wegovy to Mounjaro based on evolving treatment needs. Our prescribers evaluate factors including dose escalation stage, treatment duration, effectiveness patterns, and side effect profiles to recommend optimal switching protocols. Both medications require ongoing medical supervision regardless of treatment choice, with regular monitoring supporting long-term weight management success and safety profile maintenance throughout your treatment journey.
Complete Your Treatment Decision: Expert Support Available
Both Wegovy and Mounjaro represent evidence-based approaches to prescription weight management, available through EverydayMeds with comprehensive clinical support from our GPhC-registered pharmacy team (#9012878). Whether you're considering a change from Wegovy to Mounjaro or selecting your initial treatment, our qualified prescribers provide expert guidance based on current clinical evidence and individual medical factors. New customers access preferential pricing through code FIRST40, while returning customers benefit from DOSE25 discounts applied automatically at checkout. Our streamlined ordering process, next-day cold-chain delivery, and ongoing clinical support ensure professional treatment access regardless of your medication choice. Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and explore both treatment options with expert medical oversight.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
